论文部分内容阅读
慢性肾脏病(CKD)是心血管发病率、死亡率以及全因死亡率的独立预测因素。急性冠状动脉综合征(ACS)合并CKD较为常见,这一人群往往预后更差,死亡和出血风险更高。抗栓治疗是ACS患者的基本治疗措施,如何平衡ACS合并CKD患者的缺血和出血风险十分重要。本文结合近年临床试验研究结果和相关指南,从ACS合并CKD患者的流行病学、预后、临床表现及其抗栓药物治疗策略等方面进行阐述,旨在进一步降低不良事件风险并实现最大获益。
Chronic kidney disease (CKD) is an independent predictor of cardiovascular morbidity, mortality, and all-cause mortality. Acute coronary syndrome (ACS) with CKD is more common, and this population tends to have a worse prognosis and a higher risk of death and bleeding. Antithrombotic therapy is the primary treatment for patients with ACS, and it is important how to balance the risk of ischemia and bleeding in ACS with CKD. Based on the results of clinical trials and related guidelines in recent years, this article describes the epidemiology, prognosis, clinical manifestations and antithrombotic strategies in ACS patients with CKD to further reduce the risk of adverse events and achieve the maximum benefit.